GOLD2023

Pancreatic Cancer North America

We’ve raised enough sympathy. It’s time to raise survival rates.

aka Pancreatic Cancer North America   |   Manhattan, NY   |  https://pancreaticcancerna.org/
GuideStar Charity Check

Pancreatic Cancer North America

EIN: 84-5185853


Mission

Pancreatic Cancer North America aims to disrupt the traditional approach to discovery in pancreatic cancer by bringing together multiple sectors, innovations and novel methods to drive real change. We've waited long enough for the kind of progress people deserve. Pancreatic cancer is known as the world's toughest cancer. In fact, it is the third deadliest cancer, on target to become the second by 2030. Survival must increase more rapidly than 1-2% every decade. If we could change the odds for breast cancer in our lifetime, what is stopping us from doing the same for pancreatic cancer? PCNA is committed to working with all partners who believe as we do in coming together boldly to change the outcome for the world's toughest cancer.

Ruling year info

2020

President and CEO

Michelle Capobianco

Main address

445 5th Avenue #2873

Manhattan, NY 10018 USA

Show more contact info

Formerly known as

PancONE Network Inc

EIN

84-5185853

Subject area info

Nonprofits

Oncology

Pancreatic cancer

Medical support services

Population served info

Adults

Families

Caregivers

People with diseases and illnesses

NTEE code info

Health Support Services (E60)

IRS subsection

501(c)(3) Public Charity

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Tax forms

Show Forms 990

Communication

Programs and results

What we aim to solve

This profile needs more info.

If it is your nonprofit, add a problem overview.

Login and update

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

mRNA Pancreatic Cancer Vaccine Project

In 2017, Drs. Vinod Balachandran and Benjamin Greenbaum at Memorial Sloan Kettering Cancer Center (MSK), were working together to study what distinguishes long-term survivors of pancreatic cancer from other patients. They discovered that, up to 12 years after recovering from cancer, pancreatic cancer survivors had specialized immune cells that recognized cancer proteins called neoantigens.  The researchers thought a vaccine might be able to coax the immune system to recognize these neoantigens. The challenge was that not all patients’ tumours have the same neoantigens, making it more challenging to design than vaccines for viruses (which we saw in COVID-19).  Results from the Phase I trial suggest that the vaccines cause an effective and lasting immune response. PCNA is now funding the analysis of data from Phase 1, leverage their team of experts and design a Phase II trial with the goal of an approved vaccine therapy against pancreatic cancer - a breakthrough for this deadly cancer!

Population(s) Served
Adults
Caregivers
Families
Parents
Widows and widowers

Where we work

Financials

Pancreatic Cancer North America
Fiscal year: Jan 01 - Dec 31

Revenue vs. expenses:  breakdown

SOURCE: IRS Form 990 info
NET GAIN/LOSS:    in 
Note: When component data are not available, the graph displays the total Revenue and/or Expense values.

Liquidity in 2022 info

SOURCE: IRS Form 990

8.65

Average of 4.33 over 2 years

Months of cash in 2022 info

SOURCE: IRS Form 990

4.4

Average of 9.3 over 2 years

Fringe rate in 2022 info

SOURCE: IRS Form 990

0%

Average of 0% over 2 years

Funding sources info

Source: IRS Form 990

Assets & liabilities info

Source: IRS Form 990

Financial data

SOURCE: IRS Form 990

Pancreatic Cancer North America

Revenue & expenses

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

Fiscal year ending: cloud_download Download Data

Pancreatic Cancer North America

Balance sheet

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Fiscal year ending: cloud_download Download Data

Pancreatic Cancer North America

Financial trends analysis Glossary & formula definitions

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

This snapshot of Pancreatic Cancer North America’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.

Created in partnership with

Business model indicators

Profitability info 2021 2022
Unrestricted surplus (deficit) before depreciation $137,810 -$32,464
As % of expenses 118.7% -12.7%
Unrestricted surplus (deficit) after depreciation $137,810 -$32,464
As % of expenses 118.7% -12.7%
Revenue composition info
Total revenue (unrestricted & restricted) $254,134 $223,232
Total revenue, % change over prior year 0.0% -12.2%
Program services revenue 0.0% 0.0%
Membership dues 0.0% 0.0%
Investment income 0.0% 0.0%
Government grants 0.0% 0.0%
All other grants and contributions 100.0% 100.0%
Other revenue 0.0% 0.0%
Expense composition info
Total expenses before depreciation $116,128 $255,696
Total expenses, % change over prior year 0.0% 120.2%
Personnel 0.0% 0.0%
Professional fees 76.9% 52.3%
Occupancy 0.0% 0.0%
Interest 0.0% 0.0%
Pass-through 21.5% 32.7%
All other expenses 1.6% 15.0%
Full cost components (estimated) info 2021 2022
Total expenses (after depreciation) $116,128 $255,696
One month of savings $9,677 $21,308
Debt principal payment $0 $0
Fixed asset additions $0 $0
Total full costs (estimated) $125,805 $277,004

Capital structure indicators

Liquidity info 2021 2022
Months of cash 14.3 4.4
Months of cash and investments 14.3 4.4
Months of estimated liquid unrestricted net assets 14.3 5.0
Balance sheet composition info 2021 2022
Cash $138,334 $93,118
Investments $0 $0
Receivables $0 $20,986
Gross land, buildings, equipment (LBE) $0 $0
Accumulated depreciation (as a % of LBE) 0.0% 0.0%
Liabilities (as a % of assets) 0.0% 9.2%
Unrestricted net assets $138,334 $105,870
Temporarily restricted net assets N/A N/A
Permanently restricted net assets N/A N/A
Total restricted net assets $0 $0
Total net assets $138,334 $105,870

Key data checks

Key data checks info 2021 2022
Material data errors No No

Operations

The people, governance practices, and partners that make the organization tick.

Documents
Letter of Determination is not available for this organization
Form 1023/1024 is not available for this organization

President and CEO

Michelle Capobianco

Over the last two years while the charitable sector has grappled with the COVID-19 pandemic, Michelle has kept her eyes on the future, spearheading the development of Pancreatic Cancer North America and championing a bold approach to improving pancreatic cancer treatment options and care through unexpected partnerships and collaborations. Prior to being with Pancreatic Cancer North America and our sister organization Pancreatic Cancer Canada, Michelle was a senior staff member of the MS Society of Canada, preceded by a long-term tenure with the Easter Seals Research Institute. At these organizations, she provided leadership on numerous national new business development ventures, resulting in revenues in excess of $1M per year for the charities and a clear increase in brand recognition, employee engagement and a positive charity affiliation for corporate partners.

Number of employees

Source: IRS Form 990

Pancreatic Cancer North America

Officers, directors, trustees, and key employees

SOURCE: IRS Form 990

Compensation
Other
Related
Show data for fiscal year
Compensation data
Download up to 5 most recent years of officer and director compensation data for this organization

There are no highest paid employees recorded for this organization.

Pancreatic Cancer North America

Board of directors
as of 01/11/2024
SOURCE: Self-reported by organization
Board of directors data
Download the most recent year of board of directors data for this organization
Board chair

Ricky Ray Butler

BENLabs

Term: 2021 - 2023

Anish Kirpalani

Unity Health - St. Michael's Hospital

Russell Browne

BMO Capital Markets Precious Metals

Lauren Israel

CIBC Capital Markets

Jonathan Paul

Gluskin Sheff + Associates

Richard Weldon

Romspen Investment Corporation

Organizational demographics

SOURCE: Self-reported; last updated 8/10/2023

Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.

Leadership

The organization's leader identifies as:

Race & ethnicity
White/Caucasian/European
Gender identity
Female, Not transgender
Sexual orientation
Heterosexual or Straight
Disability status
Person without a disability

Race & ethnicity

Gender identity

Transgender Identity

Sexual orientation

Disability